Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in:

29.03.2024 | Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions

verfasst von: Josephine Harrington, G. Michael Felker, James L. Januzzi, Carolyn S. P. Lam, Ildiko Lingvay, Neha J. Pagidipati, Naveed Sattar, Harriette G. C. Van Spall, Subodh Verma, Darren K. McGuire

Erschienen in: Current Cardiology Reports | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Obesity is associated with cardiovascular (CV) conditions, including but not limited to atherosclerotic disease, heart failure, and atrial fibrillation. Despite this, the impact of intentional weight loss on CV outcomes for persons with obesity and established CV conditions remains poorly studied. New and emerging pharmacologic therapies for weight loss primarily targeting the incretin/nutrient sensing axes induce substantial and sustained weight loss. The glucagon-like-peptide 1 receptor agonists (GLP-1 RA) liraglutide and semaglutide have US FDA approval for the treatment of obesity, and the application for an obesity indication for the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide is presently under FDA review. Extensive phase II and IIIa randomized controlled trials are underway evaluating permutations of combined GLP-1 RA, GIP receptor agonist, GIP receptor antagonist, and glucagon receptor agonists. Clinical outcome trials of these therapies in persons with obesity at high risk of established CV conditions should make it possible to estimate the role of intentional weight loss in managing CV risk via these medications.

Recent Findings

High-dose once weekly injectable semaglutide (2.4 mg/week) use among persons with obesity and heart failure with preserved ejection fraction was effective at both reducing weight and improving health status; exercise capacity was also improved. Ongoing CV outcome trials of oral semaglutide and once weekly injectable tirzepatide will help to establish the role of these therapies among persons with other CV conditions. In addition to these two therapies targeting a CV claim or indication, many other new therapeutics for weight loss, as reviewed, are currently in development.

Summary

The impact of pharmacologic-induced weight loss on CV conditions for persons with obesity and established CV conditions is currently under investigation for multiple agents. These therapies may offer new avenues to manage CV risk in persons with obesity and with established or at high risk for CV disease.
Literatur
1.
2.
3.
• The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. New England Journal of Medicine. 2017;377:13–27. In an analysis of data from 68.5 million persons, high BMI was found to account for 4 million deaths globally; more than two-thirds of these deaths were due to cardiovascular disease.
4.
Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–105.
5.
Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147:e93-621.PubMedCrossRef
6.
Alexander JK, Amad KH, Cole VW. Observations on some clinical features of extreme obesity, with particular reference to cardiorespiratory effects. Am J Med. 1962;32:512–24.CrossRef
7.
Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70:921–4.PubMedCrossRef
8.
Rabbia F, Silke B, Conterno A, Grosso T, De Vito B, Rabbone I, et al. Assessment of cardiac autonomic modulation during adolescent obesity. Obes Res. 2003;11:541–8.PubMedCrossRef
9.
Abed HS, Samuel CS, Lau DH, Kelly DJ, Royce SG, Alasady M, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm. 2013;10:90–100.PubMedCrossRef
10.
Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JPM, et al. Electrophysiological, Electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol. 2015;66:1–11.PubMedCrossRef
11.
Munger TM, Dong Y-X, Masaki M, Oh JK, Mankad SV, Borlaug BA, et al. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. J Am Coll Cardiol. 2012;60:851–60.PubMedCrossRef
12.
McGill HC, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105:2712–8.PubMedCrossRef
13.
Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579–84.PubMedCrossRef
14.
Batsis JA, Sarr MG, Collazo-Clavell ML, Thomas RJ, Romero-Corral A, Somers VK, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol. 2008;102:930–7.PubMedPubMedCentralCrossRef
15.
Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride J-E, et al. Bariatric Surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: Circulation. 2021;143:1468–80.PubMed
16.
Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O’Connor PJ, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA. 2018;320:1570–82.PubMedPubMedCentralCrossRef
17.
Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28:591–8.PubMedPubMedCentralCrossRef
18.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.PubMedPubMedCentralCrossRef
19.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.PubMedCrossRef
20.
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.PubMedCrossRef
21.
22.
Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315:990–1004.PubMedCrossRef
23.
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379:1107–17.PubMedCrossRef
24.
25.
James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.PubMedCrossRef
26.
Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367:1577–9.PubMedCrossRef
27.
Blüher M, Aras M, Aronne LJ, Batterham RL, Giorgino F, Ji L, et al. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;25:2058–72.PubMedCrossRef
28.
29.
Topol EJ, Bousser M-G, Fox KA, Creager MA, Despres J-P, Easton JD, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. The Lancet. 2010;376:517–23.CrossRef
30.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394:121–30.CrossRef
31.
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet. 2018;392:1519–29.CrossRef
32.
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62.PubMedCrossRef
33.
34.
• Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–84. The STEP-HFpEF found that among persons with HF and preserved ejection fraction, 2.4 mg SC once weekly semaglutide versus placebo led to significant improvements in the co-primary outcomes of weight loss and health status as measured by the Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score.
35.
36.
37.
Eli Lilly and Company. A Phase 3, Randomized, double-blind study to investigate the efficacy and safety of once-daily oral ly3502970 compared with placebo in adult participants with obesity or overweight with weight-related comorbidities (ATTAIN-1). clinicaltrials.gov; 2023 Jul. Report No.: NCT05869903. Available from: https://​clinicaltrials.​gov/​study/​NCT05869903
38.
Eli Lilly and Company. A phase 3, open-label study of once daily LY3502970 compared with insulin glargine in adult participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. clinicaltrials.gov; 2023 Apr. Report No.: NCT05803421. Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT05803421
39.
40.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and baseline characteristics of STEP-HFpEF program evaluating semaglutide in patients with obesity HFpEF phenotype. JACC Heart Fail. 2023;11:1000–10.PubMedCrossRef
41.
42.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. cell metabolism. 2018;27:740–56.
43.
Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021;397:971–84.CrossRef
44.
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403–13.PubMedCrossRef
45.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325:1414–25.PubMedCrossRef
46.
Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022;10:193–206.PubMedCrossRef
47.
Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083–91.PubMedPubMedCentralCrossRef
48.
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–64.PubMedPubMedCentralCrossRef
49.
Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;1–8.
50.
Novo Nordisk A/S. Effect of semaglutide 2.4 mg once-weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction, and type 2 diabetes. clinicaltrials.gov; 2023 Mar. Report No.: NCT04916470. Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT04916470
51.
• Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023;31:111–22. In this study of 17,604 persons with BI ≥ 27 kg/m2 and established ASCVD, randomization to weight loss drug semaglutide resulted in a 20% reduction in the primary composite outcome of CV death, myocardial infarction, and stroke.
52.
Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–8.PubMedPubMedCentralCrossRef
53.
Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, et al. Glucagon-like peptide 1 receptor agonists and heart failure. Circulation. 2020;142:1205–18.PubMedCrossRef
54.
Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.PubMedCrossRef
55.
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51.PubMedCrossRef
56.
McGuire DK, Busui RP, Deanfield J, Inzucchi SE, Mann JFE, Marx N, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25:1932–41.PubMedCrossRef
57.
Knop FK, Aroda VR, Vale RD do, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402:705–19.
58.
Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. The Lancet. 2023;402:693–704.CrossRef
59.
Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021;20:225.PubMedPubMedCentralCrossRef
60.
Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31:410–21.PubMedCrossRef
61.
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16.PubMedCrossRef
62.
Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2023;402:613–26.CrossRef
63.
64.
McGuire DK, D’Alessio D, Nicholls SJ, Nissen SE, Riesmeyer JS, Pavo I, et al. Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. Cardiovasc Diabetol. 2022;21:163.PubMedPubMedCentralCrossRef
65.
Nicholls SJ, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2023;S0002–8703(23):00280–6.
66.
Eli Lilly and Company. Efficacy and safety of tirzepatide once weekly versus placebo after an intensive lifestyle program in participants without type 2 diabetes who have obesity or are overweight with weight-related comorbidities: a randomized, double blind, placebo-controlled Trial (SURMOUNT-3). clinicaltrials.gov; 2023 May. Report No.: NCT04657016. Available from: https://​clinicaltrials.​gov/​study/​NCT04657016
67.
Eli Lilly and Company. Efficacy and safety of tirzepatide once weekly versus placebo for maintenance of weight loss in participants without type 2 diabetes who have obesity or are overweight with weight-related comorbidities: a randomized, double-blind, placebo-controlled trial (SURMOUNT-4). clinicaltrials.gov; 2023 May. Report No.: NCT04660643. Available from: https://​clinicaltrials.​gov/​study/​NCT04660643
68.
Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402:720–30.PubMedCrossRef
69.
Novo Nordisk A/S. The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease. clinicaltrials.gov; 2023 Apr. Report No.: NCT05669755. Available from: https://​clinicaltrials.​gov/​ct2/​show/​NCT05669755
70.
Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877–88.PubMedCrossRef
71.
72.
Le Roux CW. A phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight/obesity. Presented at the American Diabetes Association's 83rd Scientific Sessions 2023.
73.
LE Roux CA, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. 51-OR: a phase 2, randomized, double-blind, placebo-controlled, dose-finding study of bi 456906 in people with overweight/obesity. Diabetes. 2023;72:51-OR.
74.
75.
76.
Altimmune, Inc. A phase 2, multicenter, randomized, double-blind, placebo-controlled and parallel group 48-week study to evaluate the efficacy and safety of ALT-801 in the treatment of obesity (MOMENTUM Trial). clinicaltrials.gov; 2022 Sep. Report No.: NCT05295875. Available from: https://​clinicaltrials.​gov/​study/​NCT05295875
77.
78.
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389:514–26.PubMedCrossRef
79.
Eli Lilly and Company. A randomized, double-blind, phase 3 study to investigate the efficacy and safety of LY3437943 once weekly compared to placebo in participants with severe obesity and established cardiovascular disease. clinicaltrials.gov; 2023 Jul. Report No.: NCT05882045. Available from: https://​clinicaltrials.​gov/​study/​NCT05882045
80.
81.
Amgen. A phase 2 randomized, placebo-controlled, double-blind, dose-ranging study to evaluate the efficacy, safety, and tolerability of AMG 133 in adult subjects with overweight or obesity, with or without type 2 diabetes mellitus. clinicaltrials.gov; 2023 Aug. Report No.: NCT05669599. Available from: https://​clinicaltrials.​gov/​study/​NCT05669599
82.
Rivus Pharmaceuticals, Inc. Exploratory Phase 2a, double-blind, placebo-controlled, dose escalation study to determine the safety, tolerability, PD, and PK of HU6 for the treatment of subjects with obese Heart Failure With Preserved Ejection Fraction (HFpEF). clinicaltrials.gov; 2023 Jun. Report No.: NCT05284617. Available from: https://​clinicaltrials.​gov/​study/​NCT05284617
Metadaten
Titel
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions
verfasst von
Josephine Harrington
G. Michael Felker
James L. Januzzi
Carolyn S. P. Lam
Ildiko Lingvay
Neha J. Pagidipati
Naveed Sattar
Harriette G. C. Van Spall
Subodh Verma
Darren K. McGuire
Publikationsdatum
29.03.2024
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 3/2024
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-02016-z

Weitere Artikel der Ausgabe 3/2024

Combined Heart Kidney Transplantation Versus Heart Transplant in Patients with Renal Failure: Contemporary Insights and Future Perspectives

  • Heart Failure (HJ Eisen, Section Editor)

Understanding the Genetic and Non-Genetic Interconnections in the Aetiology of Syndromic Congenital Heart Disease: An Updated Review: Part 2

  • Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

The Expansion of Genetic Testing in Cardiovascular Medicine: Preparing the Cardiology Community for the Changing Landscape

  • Open Access
  • Cardiovascular Genomics (KG Aragam, Section Editor)

Echogenomics: Echocardiography in Heritable Aortopathies

  • Echocardiography (JM Gardin and AH Waller, Section Editors)

Understanding the Genetic and Non-genetic Interconnections in the Aetiology of Isolated Congenital Heart Disease: An Updated Review: Part 1

  • Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Nutritional Aspects to Cardiovascular Diseases and Type 2 Diabetes Mellitus

  • Open Access
  • Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Kardiologie

Verschlechtert frühe Hyperoxie nach Reanimation die Prognose?

Kommt es sehr früh nach einer kardiopulmonalen Reanimation zu einem Zustand der Hyperoxie, ist dies bei Patienten nach einem Herzstillstand mit schlechteren funktionellen Ergebnissen assoziiert. Das zeigt eine Sekundäranalyse der TTM-2-Studie.

Lp(a) zur Risikoeinschätzung bei Thoraxschmerzen

Der Lp(a)-Wert kann dazu beitragen, bei stabilen Patienten mit neu aufgetretenen Thoraxschmerzen und ohne KHK-Diagnose die Wahrscheinlichkeit für das Vorliegen von Koronarstenosen abzuschätzen.

Finerenon bei eGFR-Verlust nicht gleich absetzen!

Der Mineralokortikoid-Rezeptor-Antagonist Finerenon verbessert die Prognose bei Herzinsuffizienz mit leicht reduzierter oder erhaltener Ejektionsfraktion. Ein Rückgang der eGFR zu Beginn der Therapie scheint diese Wirkung nicht wesentlich zu mindern.

LVAD auch bei kalt-trockener terminaler Herzinsuffizienz wirksam

Auch Personen mit kalt-trockener terminaler Herzinsuffizienz profitieren von einem linksventrikulären Unterstützungssystem (LVAD), wie Daten aus einem US-Register nahelegen. Doch es gibt Besonderheiten.     

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise